Despite advances in therapies over the past 3 decades, up to 30% of RA patients continue to live with uncontrolled disease even with frequent switching of DMARD and biological therapies suggesting that RA is a heterogeneous disease that may evolve over a lifetime. The cellular and molecular mechanisms that underlie the heterogeneity of RA are largely unknown. A detailed understanding of the pathways responsible for the differential responses of RA patients to treatment would be invaluable to facilitate the optimization of treatment regimens for individual RA patients and allow the implementation of effective `treat-to-target"""""""" approaches. This proposal will take advantage of unique cohorts of RA patients and a well-integrated multidisciplinary team of clinicians and scientists at the Hospital for Special Surgery (HSS), the New York Genome Center (NYGC) and Mount Sinai Hospital (MSH) at the University of Toronto to gain a broad understanding of the molecular pathways that control the function of these distinct cellular compartments in different clinical settings. Or major goals are to: a) utilize the unparalleled access of HSS physicians to over 26,000 surgical cases/year to obtain paired samples of peripheral blood and synovial tissues from RA and control patients undergoing surgical procedures to perform detailed cellular, molecular, and histological analyses aimed at uncovering molecular pathways whose deregulation is shared between peripheral blood samples and tissue specimens, b) exploit the phenomenon of disease worsening or flare in patients discontinuing DMARDs and biologics during the perioperative period, to perform longitudinal studies to unmask pathways that distinguish flaring vs. non-flaring patients, and c) extend the results obtained from these initial studies to cohorts of early RA patients observed longitudinally who are DMARD and/or TNF responders versus non-responders.

Public Health Relevance

These studies will provide essential information enabling a more accurate subsetting of RA patients and leading to the development of cellular/molecular signatures that can predict the responses of RA patients to therapy and guide personalized therapeutic regimens.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Exploratory/Developmental Cooperative Agreement Phase I (UH2)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Program Officer
Serrate-Sztein, Susana
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Hospital for Special Surgery
New York
United States
Zip Code
Mizoguchi, Fumitaka; Slowikowski, Kamil; Wei, Kevin et al. (2018) Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat Commun 9:789
Stephenson, William; Donlin, Laura T; Butler, Andrew et al. (2018) Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation. Nat Commun 9:791
Der, Evan; Ranabothu, Saritha; Suryawanshi, Hemant et al. (2017) Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight 2:
Rao, Deepak A; Gurish, Michael F; Marshall, Jennifer L et al. (2017) Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 542:110-114
Bykerk, Vivian P; Bingham, Clifton O; Choy, Ernest H et al. (2016) Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open 2:e000225
Curtis, J R; Yang, S; Chen, L et al. (2015) Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. Arthritis Care Res (Hoboken) 67:1345-53